Literature DB >> 20818929

The β-blocker atenolol lowers the longevity-related degree of fatty acid unsaturation, decreases protein oxidative damage, and increases extracellular signal-regulated kinase signaling in the heart of C57BL/6 mice.

Ines Sanchez-Roman1, Jose Gomez, Alba Naudi, Victoria Ayala, Manuel Portero-Otín, Monica Lopez-Torres, Reinald Pamplona, Gustavo Barja.   

Abstract

The interruption of the β-adrenergic receptor signaling at the level of adenylyl cyclase (AC) by specifically knocking out (KO) the AC5 gene activates the RAF/MEK/ extracellular signal-regulated kinase (ERK) signaling pathway, delays bone and heart aging, and increases mean and maximum longevity in mice. However, the mechanisms involved in life extension in this animal model with increased longevity have not been clarified, although a decrease in oxidative stress has been proposed as mediator. Two traits link longevity and oxidative stress. Long-lived mammals and birds have a low rate of mitochondrial reactive oxygen species (mitROS) generation and a low degree of membrane fatty acid unsaturation, but these key factors have not been studied in AC5 KO mice. In the present investigation, male C57BL/6 mice were treated with the β-blocker atenolol in drinking water, and oxidative stress-related parameters were measured in the heart. Atenolol treatment did not change the rate of mitROS production and oxidative damage to mitDNA (8-oxo-7,8-dihydro-2'-deoxyguanosine [8-oxodG]), but strongly decreased the degree of fatty acid unsaturation and the peroxidizability index, mainly due to decreases in 22:6n-3 and 20:4n-6 and to increases in 18:1n-9, 16:1n-7 and 16:0 in the atenolol group. Protein oxidation and lipoxidation were lower in the atenolol group than in the controls. The mitochondrial complex I and IV content and the amount of p-ERK1/2 signaling proteins were significantly higher in the atenolol-treated than in the control animals. These results support the idea that the increased longevity of the AC5 KO mice can be due in part to an ERK signaling-mediated stress-resistance due to a decrease in fatty acid unsaturation, leading to lower lipid peroxidation and decreased lipoxidation-derived damage to cellular proteins.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20818929     DOI: 10.1089/rej.2010.1062

Source DB:  PubMed          Journal:  Rejuvenation Res        ISSN: 1549-1684            Impact factor:   4.663


  7 in total

Review 1.  Relationship of electrophilic stress to aging.

Authors:  Piotr Zimniak
Journal:  Free Radic Biol Med       Date:  2011-06-12       Impact factor: 7.376

Review 2.  Updating the mitochondrial free radical theory of aging: an integrated view, key aspects, and confounding concepts.

Authors:  Gustavo Barja
Journal:  Antioxid Redox Signal       Date:  2013-07-03       Impact factor: 8.401

3.  Independent and additive effects of atenolol and methionine restriction on lowering rat heart mitochondria oxidative stress.

Authors:  Ines Sanchez-Roman; Alexia Gomez; Alba Naudí; Mariona Jove; Jose Gómez; Mónica Lopez-Torres; Reinald Pamplona; Gustavo Barja
Journal:  J Bioenerg Biomembr       Date:  2013-12-08       Impact factor: 2.945

Review 4.  The influence of dietary fat source on liver and skeletal muscle mitochondrial modifications and lifespan changes in calorie-restricted mice.

Authors:  José Manuel Villalba; José Alberto López-Domínguez; Yana Chen; Husam Khraiwesh; José Antonio González-Reyes; Lucía Fernández Del Río; Elena Gutiérrez-Casado; Mercedes Del Río; Miguel Calvo-Rubio; Julia Ariza; Rafael de Cabo; Guillermo López-Lluch; Plácido Navas; Kevork Hagopian; María Isabel Burón; Jon Jay Ramsey
Journal:  Biogerontology       Date:  2015-04-10       Impact factor: 4.277

5.  Lifelong treatment with atenolol decreases membrane fatty acid unsaturation and oxidative stress in heart and skeletal muscle mitochondria and improves immunity and behavior, without changing mice longevity.

Authors:  Alexia Gómez; Ines Sánchez-Roman; Jose Gomez; Julia Cruces; Ianire Mate; Mónica Lopez-Torres; Alba Naudi; Manuel Portero-Otin; Reinald Pamplona; Monica De la Fuente; Gustavo Barja
Journal:  Aging Cell       Date:  2014-02-26       Impact factor: 9.304

Review 6.  Targeting Adrenergic Receptors in Metabolic Therapies for Heart Failure.

Authors:  Dianne M Perez
Journal:  Int J Mol Sci       Date:  2021-05-28       Impact factor: 5.923

7.  Pharmacometabolomics reveals racial differences in response to atenolol treatment.

Authors:  William R Wikoff; Reginald F Frye; Hongjie Zhu; Yan Gong; Stephen Boyle; Erik Churchill; Rhonda M Cooper-Dehoff; Amber L Beitelshees; Arlene B Chapman; Oliver Fiehn; Julie A Johnson; Rima Kaddurah-Daouk
Journal:  PLoS One       Date:  2013-03-11       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.